[HTML][HTML] Thrombotic, Cardiovascular, and Microvascular Complications of Myeloproliferative Neoplasms and Clonal Hematopoiesis (CHIP): A Narrative Review
AI Schafer, DL Mann - Journal of Clinical Medicine, 2024 - pmc.ncbi.nlm.nih.gov
The most common causes of morbidity and mortality in the myeloproliferative neoplasms
(MPNs), with the exception of myelofibrosis, are venous and arterial thrombosis, as well as …
(MPNs), with the exception of myelofibrosis, are venous and arterial thrombosis, as well as …
Essential thrombocythemia in adolescents and young adults: clinical aspects, treatment options and unmet medical needs
A Iurlo, C Bucelli, D Cattaneo - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement Current treatment of essential thrombocythemia (ET) should primarily
prevent thrombo-hemorrhagic events, without increasing the rate of fibrotic progression or …
prevent thrombo-hemorrhagic events, without increasing the rate of fibrotic progression or …
Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with chronic myeloproliferative neoplasms
I Krečak, D Grohovac, NV Bašić… - Thrombosis …, 2023 - pubmed.ncbi.nlm.nih.gov
Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with
chronic myeloproliferative neoplasms Clinical presentation, treatment patterns, and outcomes …
chronic myeloproliferative neoplasms Clinical presentation, treatment patterns, and outcomes …
Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific …
Abstract BCR:: ABL1-negative myeloproliferative neoplasms (MPNs) pose a substantial risk
of thrombosis, leading to significant morbidity and mortality. Anticoagulant therapy …
of thrombosis, leading to significant morbidity and mortality. Anticoagulant therapy …
In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and atrial fibrillation: insights from the National Readmissions Database
Introduction Patients with myeloproliferative neoplasms (MPNs) and atrial fibrillation (AF) are
at increased risk of thrombosis and bleeding. However, the risk of thrombosis and bleeding …
at increased risk of thrombosis and bleeding. However, the risk of thrombosis and bleeding …
Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care
C Chung - American Journal of Health-System Pharmacy, 2023 - academic.oup.com
Purpose This article concisely evaluates current therapies that have received regulatory
approval for the treatment of classic myeloproliferative neoplasms (MPNs). Pertinent …
approval for the treatment of classic myeloproliferative neoplasms (MPNs). Pertinent …
[DOC][DOC] POLİSİTEMİA VERA
G Güneş, EA Davulcu, ZN Özdemir, DÖ İbiş, T Ercan… - file.thd.org.tr
Polisitemia vera (PV) eritropoezin kontrol mekanizmalarından bağımsız olarak eritrosit
üretiminde artış görülen klonal myeloproliferatif bir neoplazidir. Fenotipik olarak normal …
üretiminde artış görülen klonal myeloproliferatif bir neoplazidir. Fenotipik olarak normal …